Introduction
The alarmingly fast worldwide emergence of carbapenemresistant Enterobacteriaceae (CRE) is regarded as a major threat to modern medicine.
1,2 CRE commonly express multiresistant phenotypes, making the management of patients with CRE infections exceedingly difficult. In particular, the recent spread of carbapenemase-producing Klebsiella pneumoniae strains 3 underscores the urgent need for novel therapeutic options. Avibactam is a novel b-lactamase inhibitor not only exhibiting activity against Ambler class A enzymes (including KPC), but also against some class C and D enzymes, most notably OXA-48. 4 The FDA and EMA recently approved the combination of ceftazidime/avibactam for treatment of complicated urinary tract and intra-abdominal infections. Ceftazidime/avibactam might offer significant benefits for the treatment of carbapenem-resistant organisms, as compared with previously developed antimicrobials such as colistin, aminoglycosides or tigecycline. 5 Ceftazidime/ avibactam was used in the University Medical Center Hamburg-Eppendorf during an outbreak caused by a bla OXA-48 -and bla CTX-M-14 -positive K. pneumoniae strain. Here we report on the emergence of K. pneumoniae isolates exhibiting elevated ceftazidime/avibactam MICs under therapy, and provide evidence for the molecular basis of the observed nonsusceptible phenotype.
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Materials and methods

Bacterial strains
K. pneumoniae were isolated from various clinical or rectal screening specimens between October 2015 and March 2016 from four patients ( Table 1) . Species identification was performed by MALDI-TOF MS fingerprinting using a MALDI-TOF Biotyper instrument (Bruker Daltonics, Bremen, Germany). All isolates were stored at #80 C for subsequent characterization.
Susceptibility testing, phenotypic ESBL, AmpC and carbapenemase detection, analysis of efflux mechanisms and outer membrane protein analysis
Susceptibility of all isolates was tested on a Vitek II instrument (bioMérieux). MICs of carbapenems (meropenem and imipenem), ceftazidime, aminoglycosides (gentamicin, tobramycin and amikacin), tigecycline and fosfomycin were determined by gradient diffusion (Etest, bioMérieux; Liofilchem). MICs of colistin were determined by broth microdilution and all MICs determined by Etest, except those of tobramycin and gentamicin, were also verified by broth microdilution (Micronaut-S MDR MRGNScreening 2; Merlin). Ceftazidime/avibactam (30/20 lg) susceptibility was tested using a disc diffusion assay (Becton-Dickinson) and gradient diffusion strips (Liofilchem). MICs of ceftazidime and imipenem (both SigmaAldrich) each in combination with 1-16 mg/L avibactam (MedChem Express) or 5-50 mg/L PABN (Sigma-Aldrich) were determined by broth microdilution. Phenotypic detection of ESBL and AmpC enzymes was performed using double disc synergy tests [cefotaxime and ceftazidime alone and in combination with clavulanic acid (BD Diagnostic Systems) or cefpodoxime alone or in combination with clavulanic acid or boronic acid (D68C assay; Mast Diagnostica)] according to the manufacturers' instructions. Carbapenemase activity was detected by monitoring imipenem degradation with a colorimetric assay (ROSCO Rapid CARB Screen kit; Rosco) as recommended by the manufacturer. The presence of carbapenemaseencoding genes (bla KPC , bla VIM , bla NDM and bla OXA-48 ) was detected by PCR. Membrane proteins of K. pneumoniae DT1 and DT12 were isolated as previously described. 6 Outer membrane protein preparations were analysed by SDS-PAGE and protein bands corresponding in size to OmpK36, OmpK35 and OmpA were identified by MS. 6 WGS, transcriptional analysis and expression of bla CTX-M-14 and mutated alleles For WGS, total DNA of K. pneumoniae isolates DT1 and DT12 was extracted on a QiaSymphony SP instrument using QiaSymphony mericon extraction kits (Qiagen). WGS libraries were constructed with NEB NextUltra DNA library Prep Kit for Illumina (NEB) and sequenced with 2%250 cycles on an Illumina MiSeq instrument. A total of 3583958 paired-end, 251 nt Illumina MiSeq reads were generated from the Illumina MiSeq sequencer for the isolate K. pneumoniae DT12. Bases less than Q20, as well as adapter Referring to the Ambler reference amino acid numbering for class A b-lactamases, the P170S exchange in bla CTX-M-14D170D264 corresponds to a previously described P167S polymorphism.
sequences of the reads, were trimmed and any reads shorter than 126 nt were removed using Trimmomatic v0.33. 7 Retained high-quality MiSeq reads were used as input data for the SPAdes assembler (version 3.7.1), 8 resulting in 144 high-coverage and long contigs (coverage .10 and length .1000). Contigs were used as input for PLACNET, 9 resulting in several clusters. The cluster carrying bla CTX-M-14 consists of four contigs and several reference plasmids (NC_021502.1, NC_023027.1, NZ_CP015075.2, NZ_CP015071.1, NC_021488.1, NZ_CP016927.1 and NC_021078.1). Based on these reference plasmids, the four contigs were oriented to a putative plasmid using CONTIGuator v2.7. 10 All sequence gaps in the plasmid were successfully closed using GapFiller v1. 10 11 and the paired-end MiSeq reads. Rapid annotations using subsystems technology 12 analysis identified 99 putative ORFs from the putative plasmid. The plasmid harbouring bla CTX-M-14 from the isolate K. pneumoniae DT1 (with a total of 1628935 paired-end, 251 nt Illumina MiSeq reads) was assembled and annotated using the same methods described above. Sequences of bla CTX-M-14 in K. pneumoniae DT1, DT12 and additional isolates from the outbreak were verified by Sanger sequencing using primers CTX-M_seq_for and CTXM_seq_rev (Table S1 , available as Supplementary data at JAC Online).
For gene expression analysis, triplicates of K. pneumoniae strains DT1, DT10 and DT12 were grown in 20 mL of LB broth for 16 h at 37
C. Bacterial cells were harvested, washed and immersed in RNAprotect Bacteria reagent (Qiagen). Bacterial cells were lysed and RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. DNA was digested with DNA-free DNase (Ambion, Life Technologies) according to the manufacturer's instructions. Subsequently, 5 lL of DNase-digested RNA was reverse transcribed, using the iScript cDNA Synthesis Kit (Bio-Rad). Relative gene expression of two replicates of cDNA was quantified with SYBR Green Jump Start Taq Ready Mix (Sigma-Aldrich) on a Light Cycler 480 instrument (Roche Applied Science) using primer Oxa-48_for_real with Oxa-48_rev_real, CTX-M-14_for_real with CTX-M-14_rev_real, ompK35_for with ompK35_rev and ompK36_for with ompK36_rev, respectively (Table  S1 ). Relative quantification of gene expression was determined in reference to the housekeeping gene gyrA 13 from K. pneumoniae.
bla CTX-M-14 alleles including the anticipated promoter sequences were amplified from WT K. pneumoniae DT1, DT10, DT12 and OK5 using primers CTX-M-14_Clon_for and CTX-M-14_Clon_rev (Table S1 ) and ligated into vector pCR4 using the TOPO-TA-Cloning Kit (Invitrogen) or into pGEM with the pGEM-T Easy Vector Cloning System II (Promega). Plasmids designated pCR4::bla CTX-M-14 (DT1), pCR4::bla CTX-M-14 (DT12), pCR4::bla CTX-M-14 (OK5) and pGEM::bla CTX-M-14 (DT10) were all introduced into Escherichia coli TOP10.
Results
Case report and microbiological findings
A male patient in his mid-50s with chronic inflammatory bowel disease was admitted to the ICU after laparotomy and adhesiolysis. The postoperative phase was complicated by septic shock due to peritonitis with the formation of multiple interstitial fistulae. Thirty-seven days after admission to the ICU, K. pneumoniae DT1 was isolated from a pharyngeal swab obtained for screening purposes. The isolate was found to be resistant to aminopenicillins, amoxicillin/sulbactam, ceftriaxone, meropenem and imipenem and susceptible to ceftazidime ( Table 1) . The isolate was susceptible to ceftazidime/avibactam by disc diffusion [ceftazidime/avibactam (30/20 lg) inhibition zone 26 mm] and MIC (1 mg/L) testing. Double disc synergy tests (cefotaxime and ceftazidime alone and in combination with clavulanic acid; cefpodoxime alone or in combination with clavulanic acid or boronic acid) for ESBL or AmpC detection gave ambiguous results. DT1 was fully resistant to cefpodoxime and cefotaxime, as well as to inhibitor combinations thereof. Moreover, there was no increase in inhibition zone for ceftazidime and clavulanic acid, as compared with ceftazidime alone. Phenotypic analysis indicated the expression of a carbapenemase (ROSCO Rapid CARB Screen kit). Indeed, molecular analysis identified the presence of OXA-48-and CTX-M-14-encoding genes (bla OXA-48 and bla CTX-M-14 , respectively). PFGE revealed that K. pneumoniae DT1 was identical to other K. pneumoniae isolates constituting an outbreak in the ICU at that time, and thus, was most likely acquired by nosocomial transmission.
In the course of ICU treatment, calculated therapy with colistin and ceftazidime was initiated to treat a hospital-acquired pneumonia presumably caused by the carbapenem-resistant K. pneumoniae outbreak strain (Figure 1 (Table 1) . Seven weeks later, K. pneumoniae DT12 was isolated from a central venous catheter (Figure 1) . In addition to a further decrease in the ceftazidime/avibactam inhibition zone (18 mm) and an elevated MIC (32 mg/L), the isolate also exhibited a colistin MIC of 16 mg/L (Table 1) . Again, treatment with ceftazidime/avibactam in combination with meropenem was initiated (Figure 1) . Ultimately, after 7 months of ICU treatment, the clinical course was further complicated by a ventilator-associated pneumonia and a catheter-related bloodstream infection caused by Candida albicans and VRE during which the patient died.
Characterization of mechanisms related to ceftazidime/ avibactam non-susceptibility K. pneumoniae isolates DT1 and DT12 were indistinguishable by PFGE analysis. Therefore, aiming at identifying potential genomic alterations relevant to the observed phenotypic susceptibility changes, comparative WGS was performed. Both sequenced isolates were assigned to MLST ST383. K. pneumoniae DT1 and DT12 both carried bla SHV-1 and bla TEM-1B . Bioinformatics analysis found bla OXA-48 and bla CTX-M-14 located on one plasmid related to pJEG011, isolated from a K. pneumoniae in Australia.
14 The coverage of the plasmid compared with the chromosome was 1.2 in DT1 and 4.4 in DT12, indicating a change in plasmid copy number from one to approximately four in the later isolate. As compared with DT1, eight SNPs resulting in amino acid substitutions were identified in K. pneumoniae DT12 (Table S2 ). In addition, five synonymous SNPs were found. Most strikingly, two SNPs were located in bla CTX-M-14 (nt 508, C!T; nt 791, C!T; numbering according to Entrez Gene ID 15334360). Compared with sequence YP_007878535.1, SNPs lead to one amino acid change within the Ceftazidime/avibactam-non-susceptible K. pneumoniae JAC X-loop of CTX-M-14 at position 170 (P!S, referring to Ambler amino acid position 167), and a second amino acid exchange at position 264 (T!I). Both DT1 and DT12 carried WT bla OXA-48 (Entrez Gene ID 13913776). Transcriptional analysis of bla CTX-M-14 did not reveal significant changes between K. pneumoniae DT1 and DT12 (P " 0.63), and only a weak increase in expression (2.3-fold, 95% CI 1.2-4.2) of bla OXA-48 became evident in K. pneumoniae DT12 (P " 0.02), probably corresponding to the higher plasmid copy number in DT12. Therefore, the hypothesis was put forward that mutations identified in bla CTX-M-14 are relevant to the observed changes in ceftazidime and ceftazidime/avibactam susceptibilities. To test this hypothesis, WT bla CTX-M-14 and mutated bla CTX-M-14D170D264 were amplified from strains K. pneumoniae DT1 and DT12, respectively, cloned into pCR4 under control of the natural promoter, and introduced into E. coli TOP10. Expression of bla CTX-M-14D170D264 from plasmid pCR4::bla CTX-M-14 (DT12) resulted in a .64-fold increase in ceftazidime MIC (from 4 to .256 mg/L) and a 16-fold increase in ceftazidime/avibactam MIC (from 0.5 to 8 mg/L) as compared with E. coli TOP10 carrying pCR4::bla CTX-M-14 (DT1), providing evidence for a relevant contribution of the observed mutations to the increased ceftazidime and ceftazidime/avibactam MICs (Table 1) . Intriguingly, a C!T SNP at nucleotide position 508 was also identified in bla CTX-M-14 from K. pneumoniae DT10; however, this was in combination with a C!T exchange at nt 830 (resulting in an R!P amino acid exchange at position 277) ( Table 1 ). In trans expression of bla CTX-M-14D170D277 from plasmid pGEM::bla CTX-M-14 (DT10) in E. coli TOP10 also increased the ceftazidime MIC to .256 and ceftazidime/avibactam MIC to 8 mg/L ( Table 1 ), indicating that the observed CTX-M-14 alteration at amino acid position 170 is of importance for increased MICs of ceftazidime and ceftazidime/avibactam. In fact, in trans expression of bla CTX-M-14 (OK5) encoding CTX-M-14 with a single P170S exchange was sufficient to mediate full ceftazidime resistance and ceftazidime/avibactam non-susceptibility (Table 1) .
Addition of efflux pump inhibitor PABN only had a weak impact on ceftazidime/avibactam susceptibility in K. pneumoniae DT1 (2-fold ceftazidime/avibactam MIC reduction at 50 mg/L), and not in K. pneumoniae DT12. The addition of 4 mg/L avibactam to a broth microdilution of imipenem restored full susceptibility to imipenem in the clinical strains, demonstrating full inhibition of OXA-48 by avibactam (Table 1) . SDS-PAGE analysis of outer membrane proteins revealed no evidence for changes in production of major outer membrane proteins OmpK36, OmpK35 and OmpA ( Figure S1 ). In line with this finding, quantitative PCR only found a slight downregulation of ompK35 (6.3-fold; P " 0.08) and no regulation of ompK36 (P " 0.33) in K. pneumoniae DT12 as compared with DT1. Sequences of outer membrane proteins OmpK35 and OmpK36 were identical in DT1 and DT12. Thus, while certainly subtle changes in cell wall composition and efflux activity cannot be excluded, it appears that CTX-M-14 mutations are key to the observed ceftazidime/ avibactam-resistant phenotype in K. pneumoniae DT12. During the outbreak, four patients received therapy with ceftazidime/avibactam. Indeed, the crucial importance of the P170S exchange was further substantiated by its identification in other outbreak-related K. pneumoniae isolates with elevated ceftazidime/avibactam MICs that most probably emerged in three additional patients during ceftazidime or ceftazidime/avibactam therapy (Table 1 and Table S3 ).
Discussion
The introduction of the novel diazabicyclooctane class b-lactamase inhibitor avibactam presents a significant expansion of therapeutic options in infections caused by MDR Enterobacteriaceae carrying Ambler class A (e.g. ESBL enzymes, KPC), class C (AmpC) or certain class D (e.g. OXA-48) enzymes. 4, 15 The combination of avibactam with ceftazidime is approved for the treatment of complicated urinary tract and intra-abdominal infections. Recent clinical evidence supports the idea that ceftazidime/avibactam could be valuable for the treatment of infections caused by ceftazidimeresistant organisms. 5 Surveillance data suggest that resistance to ceftazidime/ avibactam in ESBL-or carbapenemase-producing E. coli and K. pneumoniae clinical isolates is rare. 16, 17 However, first reports indicate that resistance to ceftazidime/avibactam unrelated to the expression of Ambler class B enzymes occurs. [18] [19] [20] While two studies demonstrate that ceftazidime/avibactam resistance is expressed in clinical bla KPC -producing K. pneumoniae without prior exposure to the compounds, 18, 20 the emergence of resistance during therapy was recently reported in 3 of 37 patients infected with KPC-producing K. pneumoniae. 19 In the latter K. pneumoniae isolates, polymorphisms in bla KPC were related to increased ceftazidime/avibactam MICs. 21 Genetic evidence presented in this work unambiguously demonstrates that in K. pneumoniae, ceftazidime/avibactam MIC elevations near to the clinical breakpoint of 8 mg/L or even full non-susceptibility emerges in vivo through evolution of bla CTX-M-14 , resulting in enzyme isoforms exhibiting increased ceftazidime hydrolytic activity. Increased ceftazidime hydrolytic activity was also proposed as a mechanism related to ceftazidime/avibactam resistance in AmpC-producing P. aeruginosa 22 or bla KPC-3 -carrying K. pneumoniae, [23] [24] [25] but has so far not been reported to be relevant in CTX-M-14. Mutations identified here result in a P!S amino acid exchange at position 170 of CTX-M-14 (also referred to as P167S polymorphism according to Ambler amino acid numbering 26, 27 ), resulting in enhanced ceftazidime hydrolysis, thereby confirming previous findings for CTX-M-19. 28 Structural information suggests that augmented ceftazidimase activity induced by the P170S polymorphism most likely results from changes in X-loop architecture, allowing for accommodation of ceftazidime into the active site of the enzyme. 26, 27 If and how such structural changes also impact binding of avibactam 22 clearly warrants future studies, and, despite inhibition of ceftazidime hydrolysis at higher avibactam concentrations, it remains unclear if changes in avibactam affinity contribute to ceftazidime/avibactam resistance in K. pneumoniae DT12. In fact, additional amino acid changes in CTX-M-14 identified here might well contribute to an avibactam inhibition resistance, but could also be structurally relevant to the enzyme's stability, which is impaired by the P170S exchange. 29 K. pneumoniae DT10 produces a CTX-M-14 isoform carrying the P170S polymorphism without being formally resistant to ceftazidime/avibactam (MIC 8 mg/L), providing evidence that increased ceftazidimase activity is not sufficient for phenotypic ceftazidime/ avibactam resistance according to EUCAST breakpoints. In fact, in trans expression of bla CTX-M-14D170D264 from K. pneumoniae DT12 in E. coli did not result in a fully ceftazidime/avibactam-resistant phenotype, indicating the involvement of additional mechanisms (e.g. altered outer membrane protein production). 30, 31 While no gross outer membrane protein changes were observed in isolates studied here, clearly cell wall alterations associated with the mechanistically unresolved colistin resistance of K. pneumoniae DT12 could additionally support the ceftazidime/avibactam-resistant phenotype. In line with previous studies, 32, 33 addition of RND efflux pump inhibitor PABN had no measureable effect on ceftazidime MIC for K. pneumoniae isolate DT12. However, due to possible limitations of the PABN assay, the role of efflux pumps in the resistant phenotype cannot be completely excluded. 34 In addition to K. pneumoniae DT1, rapid and parallel emergence of isolates with elevated ceftazidime/avibactam MICs related to CTX-M-14 mutations was observed in three additional patients during ceftazidime therapy. Interestingly, the emergence of CTX-M isoforms with a variant hydrolysis profile is not limited to the CTX-M-9 family. In fact, in vitro studies showed that evolution of isoforms of b-lactamases belonging to the CTX-M-1 family with a higher ceftazidime hydrolysing capacity, carrying a P170 mutation seems to be favoured in certain settings. 35, 36 Given the worldwide importance of CTX-M-15, which is part of the CTX-M-1 family, and also CTX-M-14, 37 the regular selection of ceftazidime/avibactamresistant Enterobacteriaceae is not unlikely and potentially will restrict the usefulness of this combination for the treatment of infections caused by CTX-M-producing isolates.
The addition of 4 mg/L avibactam restored an imipenemsusceptible phenotype in K. pneumoniae DT1 and DT12 even after prolonged exposure, indicating that the OXA-48 enzyme remained fully susceptible to avibactam inhibition. Until now, no reports on OXA-48 isoforms resistant to inhibition by avibactam are available, and avibactam is apparently a suitable combination partner for a b-lactam antibiotic intended to treat bla OXA-48 -positive isolates. This is of specific importance in Europe where OXA-48 is the most prevalent carbapenemase encountered in Enterobacteriaceae. 38 Epidemiological evidence, however, indicates that up to 66% of all bla OXA-48 -positive isolates also carry CTX-M enzymes, of which 12.5% belong to the CTX-M-9 group. 38 Thus, a significant proportion of patients treated with ceftazidime/avibactam for OXA-48-producing Enterobacteriaceae are at risk for therapeutic failure promoted by the emergence of mutated CTX-M enzymes, as exemplified by cases discussed in the present work. Thus, to assess the risk of resistance development, a detailed analysis of b-lactamase content of clinical isolates is necessary. Moreover, it seems mandatory to monitor ceftazidime/avibactam susceptibility over the course of an infection. Finally, combination of avibactam with alternative b-lactams (e.g. carbapenems, aztreonam) could be of value for treatment of isolates expressing multiple b-lactamases. 39 
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